

Georg Hansmann

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7520375/georg-hansmann-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

200
papers

9,257
citations

31
h-index

96
g-index

229
ext. papers

11,646
ext. citations

5.1
avg, IF

6.02
L-index

#	Paper	IF	Citations
200	Interplay of Low-Density Lipoprotein Receptors, LRP6, and Lipoproteins in Pulmonary Hypertension.. <i>JACC Basic To Translational Science</i> , 2022 , 7, 164-180	8.7	0
199	Pulmonary Arterial Hypertension and Consecutive Right Heart Failure Lead to Liver Fibrosis.. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 862330	5.4	1
198	Extremely premature infants born at 23-25 weeks gestation are at substantial risk for pulmonary hypertension.. <i>Journal of Perinatology</i> , 2022 ,	3.1	1
197	Diagnosis and management of pulmonary hypertension in infants with bronchopulmonary dysplasia. <i>Seminars in Fetal and Neonatal Medicine</i> , 2022 , 101351	3.7	1
196	Circulating Interleukin-7 in Human Pulmonary Arterial Hypertension.. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 794549	5.4	
195	RNA expression profiles and regulatory networks in human right ventricular hypertrophy due to high pressure load. <i>iScience</i> , 2021 , 24, 102232	6.1	5
194	Off-label use of PAH-targeted medications approved for adults and their financial coverage by health insurances are vital for children with pulmonary hypertension. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13571	4.6	0
193	Subcostal Echocardiographic Imaging in Neonatal and Pediatric Intensive Care. <i>Frontiers in Pediatrics</i> , 2021 , 9, 471558	3.4	
192	Pulmonary hypertension in bronchopulmonary dysplasia. <i>Pediatric Research</i> , 2021 , 89, 446-455	3.2	29
191	Current Controversy on Platelets and Patent Ductus Arteriosus Closure in Preterm Infants. <i>Frontiers in Pediatrics</i> , 2021 , 9, 612242	3.4	1
190	Toward a standardized multidisciplinary team approach in preterm infants at-risk for pulmonary hypertension. <i>Journal of Perinatology</i> , 2021 , 41, 801-802	3.1	1
189	Generation of pulmonary arterial hypertension patient-specific induced pluripotent stem cell lines from three unrelated patients with a heterozygous missense mutation in exon 12, a heterozygous in-frame deletion in exon 3 and a missense mutation in exon 11 of the BMPR2 gene. <i>Stem Cell Research</i> , 2021 , 55, 102488	1.6	0
188	Soluble Receptor for Advanced Glycation End Products (sRAGE) Is a Sensitive Biomarker in Human Pulmonary Arterial Hypertension. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
187	Construction of transcriptional regulatory networks using total RNA-seq data. <i>STAR Protocols</i> , 2021 , 2, 100769	1.4	
186	Letter by Legchenko et al Regarding Article, "Transcriptomic Analysis of Right Ventricular Remodeling in Two Rat Models of Pulmonary Hypertension: Identification and Validation of Epithelial-to-Mesenchymal Transition in Human Right Ventricular Failure".. <i>Circulation: Heart Failure</i> , 2021 , 14, e008588	7.6	0
185	Mature and immature platelets during the first week after birth and incidence of patent ductus arteriosus. <i>Cardiology in the Young</i> , 2020 , 30, 769-773	1	6
184	Challenges and Special Aspects of Pulmonary Hypertension in Middle- to Low-Income Regions: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2463-2477	15.1	12

183	Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy. <i>Journal of Heart and Lung Transplantation</i> , 2020 , 39, 695-706	5.8	15
182	Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	8
181	Dringende Notwendigkeit des Off-label-Einsatzes von PAH-Medikamenten und deren Erstattung bei Kindern mit pulmonaler Hypertonie (Lungenhochdruck). <i>Monatsschrift Fur Kinderheilkunde</i> , 2020 , 168, 733-738	0.2	1
180	Red blood cell-derived semaphorin 7A promotes thrombo-inflammation in myocardial ischemia-reperfusion injury through platelet GPIb. <i>Nature Communications</i> , 2020 , 11, 1315	17.4	21
179	Trans-right ventricle and transpulmonary metabolite gradients in human pulmonary arterial hypertension. <i>Heart</i> , 2020 , 106, 1332-1341	5.1	10
178	Right ventricular end-systolic remodeling index in the assessment of pediatric pulmonary arterial hypertension. The European Pediatric Pulmonary Vascular Disease Network (EPPVDN). <i>Pediatric Research</i> , 2020 , 88, 285-292	3.2	5
177	Getting to the bottom of right heart failure. <i>Cardiovascular Diagnosis and Therapy</i> , 2020 , 10, 1517-1521	2.6	
176	Mineralocorticoid receptor blockade improves pulmonary hypertension and right ventricular function in bronchopulmonary dysplasia: a case report. <i>Cardiovascular Diagnosis and Therapy</i> , 2020 , 10, 1686-1690	2.6	2
175	Echocardiography for the Assessment of Pulmonary Hypertension and Congenital Heart Disease in the Young. <i>Diagnostics</i> , 2020 , 11,	3.8	1
174	PPAR γ is a gatekeeper for extracellular matrix and vascular cell homeostasis: beneficial role in pulmonary hypertension and renal/cardiac/pulmonary fibrosis. <i>Current Opinion in Nephrology and Hypertension</i> , 2020 , 29, 171-179	3.5	22
173	The Adult Sprague-Dawley Sugden-Hypoxia Rat Is Still "the One:" A Model of Group 1 Pulmonary Hypertension: Reply to Le Cras and Abman. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 201, 621-624	10.2	4
172	Trans-Right-Ventricle and Transpulmonary MicroRNA Gradients in Human Pulmonary Arterial Hypertension. <i>Pediatric Critical Care Medicine</i> , 2020 , 21, 340-349	3	12
171	Repurposing of medications for pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2020 , 10, 2045894-2020941494	2.7	14
170	Emerging therapies for right ventricular dysfunction and failure. <i>Cardiovascular Diagnosis and Therapy</i> , 2020 , 10, 1735-1767	2.6	5
169	Mechanics of right ventricular dysfunction in pulmonary arterial hypertension and heart failure with preserved ejection fraction. <i>Cardiovascular Diagnosis and Therapy</i> , 2020 , 10, 1580-1603	2.6	15
168	Diagnosis and treatment of right ventricular dysfunction in congenital heart disease. <i>Cardiovascular Diagnosis and Therapy</i> , 2020 , 10, 1625-1645	2.6	3
167	Interventional creation of an endogenous reverse Potts shunt in an infant with pulmonary hypertension and genetic surfactant disorder-a case report. <i>Cardiovascular Diagnosis and Therapy</i> , 2020 , 10, 1696-1700	2.6	0
166	Treatment of right ventricular dysfunction and heart failure in pulmonary arterial hypertension. <i>Cardiovascular Diagnosis and Therapy</i> , 2020 , 10, 1659-1674	2.6	6

165	Safety and efficacy of the endothelin receptor antagonist macitentan in pediatric pulmonary hypertension. <i>Cardiovascular Diagnosis and Therapy</i> , 2020 , 10, 1675-1685	2.6	10
164	Molecular mechanisms of right ventricular dysfunction in pulmonary arterial hypertension: focus on the coronary vasculature, sex hormones, and glucose/lipid metabolism. <i>Cardiovascular Diagnosis and Therapy</i> , 2020 , 10, 1522-1540	2.6	5
163	Animal models of right heart failure. <i>Cardiovascular Diagnosis and Therapy</i> , 2020 , 10, 1561-1579	2.6	4
162	Paediatric/congenital cardiology physician scientists-An endangered species. <i>European Journal of Clinical Investigation</i> , 2020 , 50, e13367	4.6	
161	Patent Ductus Arteriosus of the Preterm Infant. <i>Pediatrics</i> , 2020 , 146,	7.4	30
160	Activation of the Metabolic Master Regulator PPAR α A Potential PIONEERING Therapy for Pulmonary Arterial Hypertension. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2020 , 62, 143-156	5.7	16
159	A novel echocardiographic approach indicates disease severity in pediatric pulmonary hypertension. <i>Pediatrics International</i> , 2020 , 62, 637-639	1.2	1
158	Recommendations from the Association for European Paediatric and Congenital Cardiology for training in pulmonary hypertension. <i>Cardiology in the Young</i> , 2019 , 29, 1323-1327	1	4
157	A pediatric perspective on the TAPSE/PASP ratio in pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , 2019 , 278, 242	3.2	
156	LRP1 Deficiency in Vascular SMC Leads to Pulmonary Arterial Hypertension That Is Reversed by PPAR α Activation. <i>Circulation Research</i> , 2019 , 124, 1778-1785	15.7	28
155	Sympathetic nervous system controls resolution of inflammation via regulation of repulsive guidance molecule A. <i>Nature Communications</i> , 2019 , 10, 633	17.4	20
154	Tricuspid annular plane systolic excursion (TAPSE) in pediatric pulmonary hypertension: Integrating right ventricular ejection efficiency (RVEe) into advanced multi-parametric imaging. <i>International Journal of Cardiology</i> , 2019 , 274, 296-298	3.2	14
153	Ventricular-ventricular interaction variables correlate with surrogate variables of clinical outcome in children with pulmonary hypertension. <i>Pulmonary Circulation</i> , 2019 , 9, 2045894019854074	2.7	5
152	Emphysema Is-at the Most-Only a Mild Phenotype in the Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 200, 1447-1450	10.2	7
151	Chronic TGF- β Signaling in Pulmonary Arterial Hypertension Induces Sustained Canonical Smad3 Pathways in Vascular Smooth Muscle Cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2019 , 61, 121-123	5.7	8
150	The PPAR α agonist pioglitazone prevents TGF- β -induced renal fibrosis by repressing EGR-1 and STAT3. <i>BMC Nephrology</i> , 2019 , 20, 245	2.7	23
149	2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. <i>Journal of Heart and Lung Transplantation</i> , 2019 , 38, 879-901	5.8	133
148	Hypoxia drives cardiac miRNAs and inflammation in the right and left ventricle. <i>Journal of Molecular Medicine</i> , 2019 , 97, 1427-1438	5.5	17

147	The right ventricular outflow tract in pediatric pulmonary hypertension-Data from the European Pediatric Pulmonary Vascular Disease Network. <i>Echocardiography</i> , 2018 , 35, 841-848	1.5	3
146	PPAR α agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	113
145	Association between Platelet Counts before and during Pharmacological Therapy for Patent Ductus Arteriosus and Treatment Failure in Preterm Infants. <i>Frontiers in Pediatrics</i> , 2018 , 6, 41	3.4	10
144	Reply to "Diagnostic and prognostic value of echocardiography in pulmonary arterial hypertension". <i>Clinical Cardiology</i> , 2018 , 41, 1152-1153	3.3	
143	Echocardiographic estimation of elevated right ventricular afterload in preterm infants at risk for pulmonary hypertension: next steps. <i>Journal of Pediatrics</i> , 2018 , 202, 335-336	3.6	1
142	Different indications for transcatheter and surgical patent ductus arteriosus closure in preterm infants less than 2kg. <i>International Journal of Cardiology</i> , 2018 , 266, 83	3.2	
141	Right ventricular base/apex ratio in the assessment of pediatric pulmonary arterial hypertension: Results from the European Pediatric Pulmonary Vascular Disease Network. <i>Clinical Cardiology</i> , 2018 , 41, 1144-1149	3.3	6
140	First-in-child use of the oral soluble guanylate cyclase stimulator riociguat in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2018 , 8, 2045893217743123	2.7	25
139	Inhibition of neogenin fosters resolution of inflammation and tissue regeneration. <i>Journal of Clinical Investigation</i> , 2018 , 128, 4711-4726	15.9	17
138	Pathobiology, pathology and genetics of pulmonary hypertension: Update from the Cologne Consensus Conference 2018. <i>International Journal of Cardiology</i> , 2018 , 272S, 4-10	3.2	16
137	Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension?. <i>Pulmonary Circulation</i> , 2018 , 8, 2045894018793580	2.7	8
136	Recommendations from the Association for European Paediatric and Congenital Cardiology for clinical training in paediatric heart failure and transplantation. <i>Cardiology in the Young</i> , 2018 , 28, 1295-1298	1.98	4
135	Pulmonary Hypertension in Infants, Children, and Young Adults. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2551-2569	15.1	78
134	PPAR α links BMP2 and TGF β Pathways in Vascular Smooth Muscle Cells, Regulating Cell Proliferation and Glucose Metabolism. <i>Cell Metabolism</i> , 2017 , 25, 1118-1134.e7	24.6	97
133	First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2017 , 7, 551-554	2.7	24
132	Circulating Endothelial Cell Quantification by Microfluidics Chip in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2017 , 56, 680-682	5.7	
131	Normal Reference Values and z Scores of the Pulmonary Artery Acceleration Time in Children and Its Importance for the Assessment of Pulmonary Hypertension. <i>Circulation: Cardiovascular Imaging</i> , 2017 , 10,	3.9	48
130	Future Applications of the Selective Prostacyclin (IP) Receptor Agonist Selexipag in Pediatric Pulmonary Hypertension. <i>Pediatric Cardiology</i> , 2017 , 38, 1523-1524	2.1	1

129	Transforming Growth Factor β - and Bone Morphogenetic Protein 2/PPAR β -regulated MicroRNAs in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 1227-1228	10.2	12
128	Diagnostics in Children and Adolescents with Suspected or Confirmed Pulmonary Hypertension. <i>Paediatric Respiratory Reviews</i> , 2017 , 23, 3-15	4.8	7
127	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung	9.5	3455
126	Transthoracic echocardiography in the evaluation of pediatric pulmonary hypertension and ventricular dysfunction. <i>Pulmonary Circulation</i> , 2016 , 6, 15-29	2.7	44
125	Hemodynamic assessment and acute pulmonary vasoreactivity testing in the evaluation of children with pulmonary vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. <i>Heart</i> , 2016 , 102 Suppl 2, ii23-9	5.1	54
124	Diagnostics, monitoring and outpatient care in children with suspected pulmonary hypertension/paediatric pulmonary hypertensive vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. <i>Heart</i> , 2016 , 102 Suppl 2, ii1-19	5.1	38
123	The Need for Comprehensive Cardiac Catheterization in Children With Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1009-1010	15.1	5
122	Recent Advances in the Treatment of Preterm Newborn Infants with Patent Ductus Arteriosus. <i>Clinics in Perinatology</i> , 2016 , 43, 113-29	2.8	29
121	Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension. <i>Heart</i> , 2016 , 102, 390-6	5.1	59
120	2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016 , 69, 177	0.7	148
119	Echocardiographic Reference Values for Right Atrial Size in Children with and without Atrial Septal Defects or Pulmonary Hypertension. <i>Pediatric Cardiology</i> , 2016 , 37, 686-95	2.1	15
118	Transthoracic echocardiography for the evaluation of children and adolescents with suspected or confirmed pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. <i>Heart</i> , 2016 , 102 Suppl 2, ii1-20	5.1	50
117	Pulmonary hypertension in the intensive care unit. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. <i>Heart</i> , 2016 , 102 Suppl 2, ii57-66	5.1	38
116	Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. <i>Heart</i> , 2016 , 102 Suppl 2, ii67-85	5.1	43
115	Genetic testing and blood biomarkers in paediatric pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. <i>Heart</i> , 2016 , 102 Suppl 2, ii31-41	5.1	12
114	Pulmonary hypertension in children with congenital heart disease (PAH-CHD, PPHVD-CHD). Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. <i>Heart</i> , 2016 , 102 Suppl 2, ii13-26	5.1	43
113	Cardiac MR and CT imaging in children with suspected or confirmed pulmonary hypertension/pulmonary hypertensive vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. <i>Heart</i> , 2016 , 102 Suppl 2, ii30-5	5.1	27
112	Executive summary. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. <i>Heart</i> , 2016 , 102 Suppl 2, ii86-100	5.1	67

111	Right ventricular outflow tract velocity time integral (RVOT VTI) and tricuspid regurgitation velocity/RVOT VTI ratio in pediatric pulmonary hypertension. <i>International Journal of Cardiology</i> , 2016 , 212, 274-6	3.2	12
110	Pulmonary hypertension associated with acute or chronic lung diseases in the preterm and term neonate and infant. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. <i>Heart</i> , 2016 , 102 Suppl 2, ii49-56	5.1	52
109	Natural History of Patent Ductus Arteriosus in Very Low Birth Weight Infants after Discharge. <i>Journal of Pediatrics</i> , 2015 , 167, 1149-51	3.6	30
108	Platelet-rich plasma for the treatment of patent ductus arteriosus: not quite ready for prime time. <i>Cardiology in the Young</i> , 2015 , 25, 139-40	1	3
107	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. <i>Circulation</i> , 2015 , 132, 2037-99	13.6	1672
106	The Sugan 5416/hypoxia mouse model of pulmonary hypertension revisited: long-term follow-up. <i>Pulmonary Circulation</i> , 2014 , 4, 619-29	2.7	77
105	Interdisciplinary networks for the treatment of childhood pulmonary vascular disease: what pulmonary hypertension doctors can learn from pediatric oncologists. <i>Pulmonary Circulation</i> , 2013 , 3, 792-801	2.7	7
104	The first Keystone Symposia Conference on pulmonary vascular disease and right ventricular dysfunction: Current concepts and future therapies. <i>Pulmonary Circulation</i> , 2013 , 3, 275-7	2.7	2
103	Mesenchymal stem cell-mediated reversal of bronchopulmonary dysplasia and associated pulmonary hypertension. <i>Pulmonary Circulation</i> , 2012 , 2, 170-81	2.7	158
102	Non-Invasive Imaging for Congenital Heart Disease: Recent Innovations in Transthoracic Echocardiography. <i>Journal of Clinical & Experimental Cardiology</i> , 2012 , Suppl 8, 2	0	14
101	Thrombocytopenia in the first 24 hours after birth and incidence of patent ductus arteriosus. <i>Pediatrics</i> , 2012 , 130, e623-30	7.4	36
100	Ductal closure in neonates: a developmental perspective on platelet-endothelial interactions. <i>Blood Coagulation and Fibrinolysis</i> , 2011 , 22, 242-4	1	13
99	Design and validation of an endothelial progenitor cell capture chip and its application in patients with pulmonary arterial hypertension. <i>Journal of Molecular Medicine</i> , 2011 , 89, 971-83	5.5	36
98	Engineered alginate hydrogels for effective microfluidic capture and release of endothelial progenitor cells from whole blood. <i>Langmuir</i> , 2011 , 27, 4257-64	4	67
97	Systematic underestimation of oxygen delivery in ventilated preterm infants. <i>Neonatology</i> , 2010 , 98, 18-22	4	7
96	Patent ductus arteriosus of the preterm infant. <i>Pediatrics</i> , 2010 , 125, 1020-30	7.4	328
95	PPARgamma activation: a potential treatment for pulmonary hypertension. <i>Science Translational Medicine</i> , 2009 , 1, 12ps14	17.5	60
94			

93	Hypothermia: an evolving treatment for neonatal hypoxic ischemic encephalopathy. <i>Pediatrics</i> , 2008 , 121, 648-9; author reply 649-50	7.4	28
92	Besondere Notfallsituationen bei Frñ- und Reifgeborenen. <i>Monatsschrift Fur Kinderheilkunde</i> , 2008 , 156, 489-504	0.2	3
91	Therapeutic hypothermia in neonates. Review of current clinical data, ILCOR recommendations and suggestions for implementation in neonatal intensive care units. <i>Resuscitation</i> , 2008 , 78, 7-12	4	83
90	An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. <i>Journal of Clinical Investigation</i> , 2008 , 118, 1846-57	15.9	285
89	Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. <i>Circulation</i> , 2007 , 115, 1275-84	16.7	312
88	Neonatal resuscitation on air: it is time to turn down the oxygen tanks [corrected]. <i>Lancet, The</i> , 2004 , 364, 1293-4	40	23
87	Inhibition of hypoxia-induced apoptosis by modulation of retinoblastoma protein-dependent signaling in cardiomyocytes. <i>Circulation Research</i> , 2002 , 91, 782-9	15.7	43
86	Nucleotide-evoked relaxation of human coronary artery. <i>European Journal of Pharmacology</i> , 1998 , 359, 59-67	5.3	11
85	Characterization by antagonists of P2-receptors mediating endothelium-dependent relaxation in the rat aorta. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1997 , 356, 641-52	3.4	29
84	Vasoconstrictor and vasodilator effects of guanine nucleotides in the rat aorta. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1997 , 356, 653-61	3.4	5
83	Hemolytic disease of the newborn423-426		
82	Hydrops fetalis427-431		
81	Choanal atresia432-433		
80	Gastrointestinal obstruction437-446		
79	Necrotizing enterocolitis (NEC)447-449		
78	Omphalocele and gastroschisis450-454		
77	Neural tube defects455-459		
76	Cleft palate460-463		1

- 75 Birth trauma: brachial plexus palsy, facial nerve palsy, clavicular fracture, skull fracture, intracranial and subperiosteal hemorrhage (cephalohematoma)464-467 o
- 74 Sudden infant death syndrome (SIDS)468-471
- 73 Questions for review472-476
- 72 Transport of preterm and term infants493-503
- 71 Acute antenatal transfer504-505
- 70 Questions for review506-506
- 69 Training NICU nurses and paramedics in the neonatal emergency transport service (NETS)509-510
- 68 Training delivery room staff in the resuscitation of newborn infants511-512
- 67 Web links: societies, hospitals, guidelines and learning programs513-514
- 66 Growth charts515-515
- 65 Bilirubin diagrams and transfusion exchange limits516-516
- 64 Aortic blood pressure during the first 12h of life in infants with birth weight 610-220 g517-517
- 63 Laboratory: normal values518-524
- 62 Unit conversions525-525
- 61 An apparently trivial call from the term baby nursery243-248
- 60 Meconium aspiration269-279
- 59 Chorioamnionitis and early-onset sepsis in the newborn infant280-303
- 58 Twin-twin (feto-fetal) transfusion syndrome240-242

57 Out of hospital birth249-259

56 Perinatal hemorrhage304-309

55 Cerebral seizures317-321

54 Infants born to mothers on psychoactive substances322-324

53 Prenatal and postnatal arrhythmias325-339

52 Critical congenital cardiovascular defects340-379

51 Congenital cystic adenomatoid malformation of the lung (CAM, CCAM)417-418

50 Chylothorax419-422

49 Perinatal hypoxia-ischemia310-316

48 Hygiene in the delivery room and during neonatal transport (infection control)133-133

47 When to call a pediatrician to the delivery room134-135

46 Assigning individual duties in the delivery room140-141

45 Checklist for the postnatal treatment of newborn infants136-139

44 Cardiopulmonary resuscitation of newborn infants at birth150-172

43 Volume therapy and sodium bicarbonate supplementation in preterm and term newborn infants173-178

42 Mechanical ventilation of the neonate193-209

41 Questions for review (basics)210-211

40 Clinical assessment of the newborn infant142-149

- 39 Absolute and relative indications for neonatal transport and NICU admission 179-180
- 38 Communication with mother and father 181-181
- 37 Coordinating neonatal transport and patient sign-out to the NICU team 182-182
- 36 Documentation and feedback after neonatal emergency transport 183-183
- 35 Ethics in neonatal intensive care 184-190
- 34 Perinatal images of preterm and term infants 191-192
- 33 Management of healthy, term newborn infants (vaginal delivery, cesarean section, vacuum extraction, forceps delivery) 221-226
- 32 Management of preterm and moderately depressed term newborn infants with a birth weight ≤ 500 g 227-230
- 31 Management of very preterm newborn infants (VLBW, ELBW) 231-239
- 30 Interdisciplinary approach for neonatal emergencies 5-8
- 29 Coordinating health care providers after a neonatal emergency call 11-12
- 28 What the neonatologist would like to find in the delivery room 13-14
- 27 What the neonatologist does not want to find in the delivery room 15-15
- 26 Definitions and abbreviations in neonatology, pediatric cardiology, neonatal emergency transport service (NETS), and obstetrics 16-23
- 25 Basic equipment setup for initial neonatal care and resuscitation 25-40
- 24 Drugs for neonatal emergencies 41-62
- 23 Suctioning 67-70
- 22 Stimulation, oxygen supplementation, bag-and-mask ventilation (M-PPV), pharyngeal/bi-nasal CPAP, and pharyngeal positive pressure ventilation 71-81

- 21 Endotracheal intubation and gastric tube placement 82-95 1
- 20 Chest compressions 101-104
- 19 Peripheral venous access 105-106
- 18 Umbilical vein/artery catheterization (UVC, UAC) 107-111
- 17 Neonatal emergency call: what the neonatology team would like to know from obstetricians and midwives 9-10
- 16 Postnatal cardiopulmonary adaptation 63-66
- 15 Central venous access (internal jugular vein) 112-116
- 14 Intraosseous access 117-120
- 13 Cord clamping 121-123
- 12 Management of high-risk infants in the delivery room 124-130
- 11 Monitoring in the delivery room and during neonatal transport 131-132
- 10 History and challenges of neonatal emergency transport services (NETS) 1-4
- 9 Esophageal atresia 434-436
- 8 Persistent pulmonary hypertension of the newborn (PPHN) 392-403
- 7 Patent ductus arteriosus of the preterm infant 380-391
- 6 Laryngeal mask airway (LMA) 96-100
- 5 References (Section 1) 24-24
- 4 References (Section 2) 212-220

3 References (Section 4)507-508

2 References (Section 5)526-526

1 References (Section 3)477-492